MR Fingerprinting for Vestibular Schwannomas

Vestibular Schwannoma Clinical Trial

Official title:

MR-Fingerprinting for the Prediction of the Response of Vestibular Schwannomas to Gamma Knife Radiosurgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04851925
• Other study ID #: EK2451/2020
• Status: Recruiting
• Start date: February 24, 2021
• Est. completion date: December 24, 2025

Study information

• Verified date: January 2024
• Source: Medical University of Vienna
• Contact: Dorian Hirschmann, MD
• Phone: +4314040025780
• Email: dorian.hirschmann[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

MR Fingerprinting (MRF) will be performed in patients who will be treated with Gamma Knife radio surgery for a vestibular schwannoma before the intervention. Fifty patients will be included with a vestibular schwannoma of minimum 1cm in size. During follow-up, response of the tumor to radiosurgery will be evaluated for each patient with MRI. The aim of the study is to find patterns of vestibular schwannomas in MRF data which correlate with the type of response to radio surgery, i.e. tumor control after radiosurgery, further tumor growth despite radiosurgery, cystic transformation after radiosurgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 24, 2025
• Est. primary completion date: December 24, 2025
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria: Planned Gamma Knife radiosurgery for vestibular schwannoma of minimum 1cm in size -

Exclusion Criteria: Vestibular Schwannoma of less than 1cm in size. Other a priori treatment than Gamma Knife radiosurgery

-

Related Conditions & MeSH terms

• Neurilemmoma
• Neuroma, Acoustic
• Vestibular Schwannoma

Intervention

Other:
• MR Fingerprinting
Specific Magnetic Resonance Imaging protocol

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor control	Number of patients without further growth of the tumor on follow-up MRI after radiosurgery	3 years
Primary	Tumor growth	Number of patients with growth of the tumor on follow-up MRI after radiosurgery	3 years
Primary	Cystic transformation	Number of patients with cystic transformation of the tumor on follow-up MRI after radiosurgery	3 years